{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:42:01Z","timestamp":1772077321950,"version":"3.50.1"},"reference-count":13,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,6,5]]},"published-print":{"date-parts":[[2024,9]]},"DOI":"10.2967\/jnumed.124.267462","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T16:05:45Z","timestamp":1720713945000},"page":"1423-1426","source":"Crossref","is-referenced-by-count":4,"title":["Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After<sup>177<\/sup>Lu-DOTATATE Therapy"],"prefix":"10.2967","volume":"65","author":[{"given":"Andrew F.","family":"Voter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"De Jesus-Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"2024090306450628000_65.9.1423.1","doi-asserted-by":"crossref","unstructured":"Tsoli M Chatzellis E Koumarianou A Kolomodi D Kaltsas G . Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2018;10:2042018818804698.","DOI":"10.1177\/2042018818804698"},{"key":"2024090306450628000_65.9.1423.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.1514"},{"key":"2024090306450628000_65.9.1423.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2024090306450628000_65.9.1423.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.119347"},{"key":"2024090306450628000_65.9.1423.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.189712"},{"key":"2024090306450628000_65.9.1423.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2024090306450628000_65.9.1423.7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00257447","article-title":"Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer","volume":"24","author":"Figoli","year":"1989","journal-title":"Cancer Chemother Pharmacol."},{"key":"2024090306450628000_65.9.1423.8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.critrevonc.2009.03.004","article-title":"Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey","volume":"72","author":"Repetto","year":"2009","journal-title":"Crit Rev Oncol Hematol."},{"key":"2024090306450628000_65.9.1423.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3193-4"},{"key":"2024090306450628000_65.9.1423.10","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2016.2035"},{"key":"2024090306450628000_65.9.1423.11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clgc.2016.07.027","article-title":"Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial","volume":"15","author":"Vogelzang","year":"2017","journal-title":"Clin Genitourin Cancer."},{"key":"2024090306450628000_65.9.1423.12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res."},{"key":"2024090306450628000_65.9.1423.13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/j.seminhematol.2015.06.001","article-title":"Evaluation of macrocytic anemias","volume":"52","author":"Green","year":"2015","journal-title":"Semin Hematol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:46:34Z","timestamp":1725371194000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.2967\/jnumed.124.267462"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267462","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}